Watson To Pay $5.6B For Generic-Drug Maker Actavis

Law360, New York (April 25, 2012, 7:37 PM EDT) -- New Jersey-based Watson Pharmaceuticals Inc. has agreed to buy Swiss drugmaker Actavis Group for €4.25 billion (about $5.6 billion) in a deal that would create the world's third-largest generic pharmaceuticals maker, with about $8 billion in revenue, the companies said Wednesday.

The acquisition will expand Watson's reach into markets in Russia and Central and Eastern Europe and boost the company's share of revenue from overseas from 16 percent to 40 percent of total generic net revenue, the companies said.

The combined company will have more than...
To view the full article, register now.